APIC 2016: Recap, News and Highlights
The annual APIC conference was held June 10-13 in Charlotte, North Carolina. Leading infection preventionists from across the country gathered to learn about the newest practices and technologies to keep patients and staff safe in their hospital facilities. Tru-D enjoyed meeting attendees and learning from leading researchers in health care. Below are some of Tru-D’s top takeaways:
Responsibility for the Future
Among the key takeaways of the event was a challenge by Dr. William A. Rutala to eliminate all hospital-acquired infections related to instruments and the environment within 5 years through research, technology automation and competency.
“We know that we have evidence that the environment contributes to HAIs. We also know surfaces are contaminated about 25% of the time. We know these pathogens can survive for days, weeks and months, and contact with these surfaces results in contamination. We know disinfection reduces HAIs. We also know that rooms are not being adequately clean. And admission to a room that had a pathogen, results in the new patient having an increased risk of acquiring an HAI by 39-300%,” said Rutala.
So, how will we eliminate the environment as a cause of HAIs?
“We have to consider no-touch technology to supplement, but not replace, surface disinfection,” said Rutala. “This technology should be used for terminal room disinfection after discharge of patients on contact precautions.”
Rutala went on to discuss the only randomized, clinical trial on UV: the Benefits of Enhanced Terminal Room Disinfection (BETR-D) study funded by the CDC, for which Tru-D was the only device selected.
The study proved that, “enhanced terminal room strategies decreased the incidence of target MDROs by 10-30%.”
The Importance of Measuring Dose
When asked whether measuring UV dose was important, Deverick Anderson, MD noted that some devices “measure your time and distance” while others measure dose. He continued, “Because the size of the room may change, one size fits all may not be the best approach.”
With its Sensor360 technology, Tru-D is able to overcome room variables including size, shape and contents to deliver the precise, lethal dose of UV light needed. Read more here.
Understanding and Interpreting Research Studies
Terri Rebmann, PhD, RN, CIC from the Institute for Biosecurity at St. Louis University stressed the importance of looking at key attributes of studies to determine decisions, asking the question: what is the study design?
According to Rebmann, a randomized study is “rare” yet strong in its design and should be considered as viable evidence for a product’s effectiveness.
As the only device selected for the first-ever randomized, clinical trial on UV disinfection, Tru-D continues to be backed by sound science.